Neutralizing antibodies against SARS-CoV-2 are higher but decline faster in mRNA vaccinees compared to individuals with natural infection
<h3>Background</h3><p dir="ltr">Waning protection against emerging SARS-CoV-2 variants by pre-existing antibodies elicited because of current vaccination or natural infection is a global concern. Whether this is due to the waning of immunity to SARS-COV-2 remains unclear....
محفوظ في:
| المؤلف الرئيسي: | |
|---|---|
| مؤلفون آخرون: | , , , , , , , , , , , |
| منشور في: |
2022
|
| الموضوعات: | |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
| _version_ | 1864513563211595776 |
|---|---|
| author | Haissam Abou-Saleh (497840) |
| author2 | Bushra Y Abo-Halawa (14619731) Salama Younes (14619758) Nadin Younes (4863280) Duaa W. Al-Sadeq (10976754) Farah M Shurrab (14619787) Na Liu (102929) Hamda Qotba (12794976) Nader Al-Dewik (4166527) Ahmed Ismail (2671822) Hadi M Yassine (85827) Laith J Abu-Raddad (11868161) Gheyath K Nasrallah (14723289) |
| author2_role | author author author author author author author author author author author author |
| author_facet | Haissam Abou-Saleh (497840) Bushra Y Abo-Halawa (14619731) Salama Younes (14619758) Nadin Younes (4863280) Duaa W. Al-Sadeq (10976754) Farah M Shurrab (14619787) Na Liu (102929) Hamda Qotba (12794976) Nader Al-Dewik (4166527) Ahmed Ismail (2671822) Hadi M Yassine (85827) Laith J Abu-Raddad (11868161) Gheyath K Nasrallah (14723289) |
| author_role | author |
| dc.creator.none.fl_str_mv | Haissam Abou-Saleh (497840) Bushra Y Abo-Halawa (14619731) Salama Younes (14619758) Nadin Younes (4863280) Duaa W. Al-Sadeq (10976754) Farah M Shurrab (14619787) Na Liu (102929) Hamda Qotba (12794976) Nader Al-Dewik (4166527) Ahmed Ismail (2671822) Hadi M Yassine (85827) Laith J Abu-Raddad (11868161) Gheyath K Nasrallah (14723289) |
| dc.date.none.fl_str_mv | 2022-12-01T00:00:00Z |
| dc.identifier.none.fl_str_mv | 10.1093/jtm/taac130 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/journal_contribution/Neutralizing_antibodies_against_SARS-CoV-2_are_higher_but_decline_faster_in_mRNA_vaccinees_compared_to_individuals_with_natural_infection/22099271 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Biomedical and clinical sciences Medical microbiology Pharmacology and pharmaceutical sciences mRNA vaccines waning neutralizing antibody Anti-S1-IgA SRBD-IgM |
| dc.title.none.fl_str_mv | Neutralizing antibodies against SARS-CoV-2 are higher but decline faster in mRNA vaccinees compared to individuals with natural infection |
| dc.type.none.fl_str_mv | Text Journal contribution info:eu-repo/semantics/publishedVersion text contribution to journal |
| description | <h3>Background</h3><p dir="ltr">Waning protection against emerging SARS-CoV-2 variants by pre-existing antibodies elicited because of current vaccination or natural infection is a global concern. Whether this is due to the waning of immunity to SARS-COV-2 remains unclear.</p><h3>Aim</h3><p dir="ltr">We aimed to investigate the dynamics of antibody isotype responses amongst vaccinated naïve (VN) and naturally infected (NI) individuals.</p><h3>Methods</h3><p dir="ltr">We followed up antibody levels in COVID-19 messenger RNA (mRNA)-vaccinated subjects without prior infection (VN, <i>n</i> = 100) in two phases: phase-I (P-I) at ~ 1.4 and phase-II (P-II) at ~ 5.3 months. Antibody levels were compared with those of unvaccinated and naturally infected subjects (NI, <i>n</i> = 40) at ~ 1.7 (P-1) and 5.2 (P-II) months post-infection. Neutralizing antibodies (NTAb), anti-S-RBD-IgG, -IgM and anti-S-IgA isotypes were measured.</p><h3>Results</h3><p dir="ltr">The VN group elicited significantly greater antibody responses (<i>P</i> < 0.001) than the NI group at P-I, except for IgM. In the VN group, a significant waning in antibody response was observed in all isotypes. There was about an ~ 4-fold decline in NTAb levels (<i>P</i> < 0.001), anti-S-RBD-IgG (~5-fold, <i>P</i> < 0.001), anti-S-RBD-IgM (~6-fold, <i>P</i> < 0.001) and anti-S1-IgA (2-fold, <i>P</i> < 0.001). In the NI group, a significant but less steady decline was notable in S-RBD-IgM (~2-fold, <i>P</i> < 0.001), and a much smaller but significant difference in NTAb (<2-fold, <i>P</i> < 0.001) anti-S-RBD IgG (<2-fold, <i>P</i> = 0.005). Unlike the VN group, the NI group mounted a lasting anti-S1-IgA response with no significant decline. Anti-S1-IgA, which were ~ 3-fold higher in VN subjects compared with NI in P-1 (<i>P</i> < 0.001), dropped to almost the same levels, with no significant difference observed between the two groups in P-II.</p><h3>Conclusion</h3><p dir="ltr">Whereas double-dose mRNA vaccination boosted antibody levels, vaccinated individuals’ ‘boost’ was relatively short-lived.</p><h2>Other information</h2><p dir="ltr">Published in: Journal of Travel Medicine<br>License: <a href="http://creativecommons.org/licenses/by/4.0" target="_blank">https://creativecommons.org/licenses/by/4.0</a><br>See article on publisher's website: <a href="http://dx.doi.org/10.1093/jtm/taac130" target="_blank">http://dx.doi.org/10.1093/jtm/taac130</a></p><p dir="ltr">Additional institutions affiliated with: WHO Collaborating Centre for Disease Epidemiology Analytics on HIV/AIDS, Sexually Transmitted Infections, and Viral Hepatitis - WCM-Q</p> |
| eu_rights_str_mv | openAccess |
| id | Manara2_6c3978685e508da194064cb589302562 |
| identifier_str_mv | 10.1093/jtm/taac130 |
| network_acronym_str | Manara2 |
| network_name_str | Manara2 |
| oai_identifier_str | oai:figshare.com:article/22099271 |
| publishDate | 2022 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | Neutralizing antibodies against SARS-CoV-2 are higher but decline faster in mRNA vaccinees compared to individuals with natural infectionHaissam Abou-Saleh (497840)Bushra Y Abo-Halawa (14619731)Salama Younes (14619758)Nadin Younes (4863280)Duaa W. Al-Sadeq (10976754)Farah M Shurrab (14619787)Na Liu (102929)Hamda Qotba (12794976)Nader Al-Dewik (4166527)Ahmed Ismail (2671822)Hadi M Yassine (85827)Laith J Abu-Raddad (11868161)Gheyath K Nasrallah (14723289)Biomedical and clinical sciencesMedical microbiologyPharmacology and pharmaceutical sciencesmRNA vaccineswaningneutralizing antibodyAnti-S1-IgASRBD-IgM<h3>Background</h3><p dir="ltr">Waning protection against emerging SARS-CoV-2 variants by pre-existing antibodies elicited because of current vaccination or natural infection is a global concern. Whether this is due to the waning of immunity to SARS-COV-2 remains unclear.</p><h3>Aim</h3><p dir="ltr">We aimed to investigate the dynamics of antibody isotype responses amongst vaccinated naïve (VN) and naturally infected (NI) individuals.</p><h3>Methods</h3><p dir="ltr">We followed up antibody levels in COVID-19 messenger RNA (mRNA)-vaccinated subjects without prior infection (VN, <i>n</i> = 100) in two phases: phase-I (P-I) at ~ 1.4 and phase-II (P-II) at ~ 5.3 months. Antibody levels were compared with those of unvaccinated and naturally infected subjects (NI, <i>n</i> = 40) at ~ 1.7 (P-1) and 5.2 (P-II) months post-infection. Neutralizing antibodies (NTAb), anti-S-RBD-IgG, -IgM and anti-S-IgA isotypes were measured.</p><h3>Results</h3><p dir="ltr">The VN group elicited significantly greater antibody responses (<i>P</i> < 0.001) than the NI group at P-I, except for IgM. In the VN group, a significant waning in antibody response was observed in all isotypes. There was about an ~ 4-fold decline in NTAb levels (<i>P</i> < 0.001), anti-S-RBD-IgG (~5-fold, <i>P</i> < 0.001), anti-S-RBD-IgM (~6-fold, <i>P</i> < 0.001) and anti-S1-IgA (2-fold, <i>P</i> < 0.001). In the NI group, a significant but less steady decline was notable in S-RBD-IgM (~2-fold, <i>P</i> < 0.001), and a much smaller but significant difference in NTAb (<2-fold, <i>P</i> < 0.001) anti-S-RBD IgG (<2-fold, <i>P</i> = 0.005). Unlike the VN group, the NI group mounted a lasting anti-S1-IgA response with no significant decline. Anti-S1-IgA, which were ~ 3-fold higher in VN subjects compared with NI in P-1 (<i>P</i> < 0.001), dropped to almost the same levels, with no significant difference observed between the two groups in P-II.</p><h3>Conclusion</h3><p dir="ltr">Whereas double-dose mRNA vaccination boosted antibody levels, vaccinated individuals’ ‘boost’ was relatively short-lived.</p><h2>Other information</h2><p dir="ltr">Published in: Journal of Travel Medicine<br>License: <a href="http://creativecommons.org/licenses/by/4.0" target="_blank">https://creativecommons.org/licenses/by/4.0</a><br>See article on publisher's website: <a href="http://dx.doi.org/10.1093/jtm/taac130" target="_blank">http://dx.doi.org/10.1093/jtm/taac130</a></p><p dir="ltr">Additional institutions affiliated with: WHO Collaborating Centre for Disease Epidemiology Analytics on HIV/AIDS, Sexually Transmitted Infections, and Viral Hepatitis - WCM-Q</p>2022-12-01T00:00:00ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.1093/jtm/taac130https://figshare.com/articles/journal_contribution/Neutralizing_antibodies_against_SARS-CoV-2_are_higher_but_decline_faster_in_mRNA_vaccinees_compared_to_individuals_with_natural_infection/22099271CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/220992712022-12-01T00:00:00Z |
| spellingShingle | Neutralizing antibodies against SARS-CoV-2 are higher but decline faster in mRNA vaccinees compared to individuals with natural infection Haissam Abou-Saleh (497840) Biomedical and clinical sciences Medical microbiology Pharmacology and pharmaceutical sciences mRNA vaccines waning neutralizing antibody Anti-S1-IgA SRBD-IgM |
| status_str | publishedVersion |
| title | Neutralizing antibodies against SARS-CoV-2 are higher but decline faster in mRNA vaccinees compared to individuals with natural infection |
| title_full | Neutralizing antibodies against SARS-CoV-2 are higher but decline faster in mRNA vaccinees compared to individuals with natural infection |
| title_fullStr | Neutralizing antibodies against SARS-CoV-2 are higher but decline faster in mRNA vaccinees compared to individuals with natural infection |
| title_full_unstemmed | Neutralizing antibodies against SARS-CoV-2 are higher but decline faster in mRNA vaccinees compared to individuals with natural infection |
| title_short | Neutralizing antibodies against SARS-CoV-2 are higher but decline faster in mRNA vaccinees compared to individuals with natural infection |
| title_sort | Neutralizing antibodies against SARS-CoV-2 are higher but decline faster in mRNA vaccinees compared to individuals with natural infection |
| topic | Biomedical and clinical sciences Medical microbiology Pharmacology and pharmaceutical sciences mRNA vaccines waning neutralizing antibody Anti-S1-IgA SRBD-IgM |